An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016.
- 23 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.